Predictors of response to interferon therapy

被引:16
作者
Saracco, G [1 ]
Rizzetto, M [1 ]
机构
[1] MOLINETTE MAURIZIANO HOSP,DEPT GASTROENTEROL,I-10126 TURIN,ITALY
关键词
interferon; chronic hepatitis C; predictive factors; HCV genotypes;
D O I
10.1007/BF02087886
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
An optimal treatment schedule is the first factor that influences sustained responses to interferon (IFN) therapy. There is growing evidence that prolonged IFN therapy (at least 12 months or longer) increases the sustained response rate. A low viremia at baseline favorably affects the long-term response to IFN. High viral replication does not preclude response, but highly viremic patients tend not to sustain their response. Patients with genotypes 2 and 3 (Simmonds classification) have an improved likelihood of responding compared to patients with genotype 1; unfortunately, genotype 1 predominates in Western countries. The ''quasi-species'' diversity of hepatitis C virus (HCV) may play a role in determining response to IFN, which is more likely in patients with lesser degrees of HCV diversity. However, studying the nucleotide diversity of the hypervariable region 1 of HCV is a very complex and expensive process that cannot be applied to a large number of patients. The sustained response rate is higher in patients with mild disease than in cirrhotic patients. Cirrhotics should be treated with caution, since IFN therapy could induce serious side effects and decompensation. Baseline predictive factors of response are useful to improve the cost-benefit ratio of IFN therapy but cannot be considered inclusion/exclusion criteria. The decision on how to treat should be based upon the individual characteristics of each patient.
引用
收藏
页码:S115 / S120
页数:6
相关论文
共 63 条
[41]   CONTINUOUS VERSUS INTERMITTENT THERAPY FOR CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON ALFA-2A [J].
NEGRO, F ;
BALDI, M ;
MONDARDINI, A ;
LEANDRO, G ;
CHANEAC, M ;
MANZINI, P ;
ABATE, ML ;
ZAHM, F ;
DASTOLI, G ;
BALLARE, M ;
RYFF, JC ;
VERME, G ;
BONINO, F .
GASTROENTEROLOGY, 1994, 107 (02) :479-485
[42]   THE DEGREE OF VARIABILITY IN THE AMINO TERMINAL REGION OF THE E2/NS1 PROTEIN OF HEPATITIS-C VIRUS CORRELATES WITH RESPONSIVENESS TO INTERFERON THERAPY IN VIREMIC PATIENTS [J].
OKADA, S ;
AKAHANE, Y ;
SUZUKI, H ;
OKAMOTO, H ;
MISHIRO, S .
HEPATOLOGY, 1992, 16 (03) :619-624
[43]   HEPATIC IRON CONCENTRATION AS A PREDICTOR OF RESPONSE TO INTERFERON-ALFA THERAPY IN CHRONIC HEPATITIS-C [J].
OLYNYK, JK ;
REDDY, KR ;
DIBISCEGLIE, AM ;
JEFFERS, LJ ;
PARKER, TI ;
RADICK, JL ;
SCHIFF, ER ;
BACON, BR .
GASTROENTEROLOGY, 1995, 108 (04) :1104-1109
[44]  
PAGLIARO L, 1994, HEPATOLOGY, V19, P820, DOI 10.1002/hep.1840190404
[45]   A COMPARISON OF 3 INTERFERON ALFA-2B REGIMENS FOR THE LONG-TERM TREATMENT OF CHRONIC NON-A, NON-B-HEPATITIS [J].
POYNARD, T ;
BEDOSSA, P ;
CHEVALLIER, M ;
MATHURIN, P ;
LEMONNIER, C ;
TREPO, C ;
COUZIGOU, P ;
PAYEN, JL ;
SAJUS, M ;
COSTA, JM ;
VIDAUD, M ;
CHAPUT, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (22) :1457-1462
[46]   HEPATITIS-C VIRUS GENOTYPES IN FRANCE - COMPARISON OF CLINICAL-FEATURES OF PATIENTS INFECTED WITH HCV TYPE-I AND TYPE-II [J].
QU, D ;
LI, JS ;
VITVITSKI, L ;
MECHAI, S ;
BERBY, F ;
TONG, SP ;
BAILLY, F ;
WANG, QS ;
MARTIN, JL ;
TREPO, C .
JOURNAL OF HEPATOLOGY, 1994, 21 (01) :70-75
[47]  
REICHARD O, 1994, HEPATOLOGY, V19, P280
[48]  
REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1002/hep.1840210405
[49]  
SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1016/0270-9139(91)92448-H
[50]   SEQUENTIAL CHANGE OF THE HYPERVARIABLE REGION OF THE HEPATITIS-C VIRUS GENOME IN ACUTE INFECTION [J].
SAKAMOTO, N ;
ENOMOTO, N ;
KUROSAKI, M ;
MARUMO, F ;
SATO, C .
JOURNAL OF MEDICAL VIROLOGY, 1994, 42 (01) :103-108